Massachusetts-based Karuna Therapeutics, a clinical-stage pharmaceutical company, has secured $68 million in Series B funding round.
The company intends to use the money raised to accelerate the clinical development of a radically different drug for schizophrenia.
In August last year, Karuna bagged $42 million in Series A funding for development of the experimental medicine.
To date, the company has nabbed a total of $118.6 million in over four funding rounds.